Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP -Deleted KRAS -Mutant Pancreatic Cancer

Kristina Drizyte‐Miller; Lars D. Engstrom; Jeffrey A. Klomp; Clint A. Stalnecker; Addison G. Stamey; Khalilah E. Taylor; Mallory K. Roach; Ryan Robb; Laura Waters; Andrew Calinisan; Seamus Degan; Wen-Hsuan Chang; Xousaen M. Helu; David Nguyen; Elisa Baldelli; Mariaelena Pierobon; Emanuel F. Petricoin; David M. Briere; Jill Hallin; James G. Christensen; Kirsten L. Bryant; Adrienne D. Cox; Peter Olson; Channing J. Der

doi:10.1158/0008-5472.can-25-1507

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

MTAP deletion and mutational activation of KRAS create therapeutic vulnerabilities for MTA-cooperative PRMT5 and mutant-selective KRAS inhibitors, respectively, providing the rationale for their combination therapy for MTAP-deleted, KRAS-mutant pancreatic cancer. See related article by Knoll et al., p. 3518.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Drizyte‐Miller et al. (2025) studied this question.

synapsesocial.com/papers/69dbd1e27d378569a9836112 https://doi.org/10.1158/0008-5472.can-25-1507

View Full Paper

Ask AI

Bookmark

Share

Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP -Deleted KRAS -Mutant Pancreatic Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP -Deleted KRAS -Mutant Pancreatic Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading